Targeting Inflammation for Endometrial Cancer Prevention

Status Active, not recruiting

Clinical Trial Summary

This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To develop a model for a biobank that can be expanded across the Mayo Enterprise and implemented at extramural collaborative sites, including underserved populations. OUTLINE: This is an observational study. Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05407025
Study type	Observational
Source	Mayo Clinic
Contact
Status	Active, not recruiting
Phase
Start date	December 1, 2021
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Completed	`NCT00729586` - Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	Phase 2
Completed	`NCT00756847` - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors	Phase 1
Completed	`NCT02983279` - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer	N/A
Completed	`NCT02017353` - Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma	Phase 2
Completed	`NCT00997373` - Letrozole as a Treatment of Endometrial Cancer	N/A
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Recruiting	`NCT04576104` - Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer	Phase 2
Not yet recruiting	`NCT06102252` - Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma	N/A
Active, not recruiting	`NCT02598219` - Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.	Phase 3
Recruiting	`NCT04159155` - A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer	Phase 2/Phase 3
Recruiting	`NCT05139368` - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer	N/A
Recruiting	`NCT02611024` - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors	Phase 1/Phase 2
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Suspended	`NCT06253494` - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03917381` - GEN1046 Safety Trial in Patients With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03372720` - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors	N/A
Recruiting	`NCT06413992` - Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer	Phase 2
Recruiting	`NCT05316467` - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma	Phase 2/Phase 3